Table 2.

Cross-sensitivity of cisplatin-resistant deletion strains to other cytotoxic agents

Gene/ORF5-FUDoxorubicinCamptothecinMNNG
FCY2+5+1.500
HPT1+2.5000
UPF10+2+1.5−1.5
NMD20+2+1.5−1.5
UPF30+1.5+1.5−2
SKI3−3+1.5+1.5−2
YGL214W−2+2+1.5−4
SKI8−2+1.5+1.5−3
NOT30−20−3
SOK1+20−1.50
STP1−1.5−4−1.5−2
YJL175W−3−2+20
SKY1−5+20−4
ITR1−1.5+2−1.5−10
VPS29−1.5−2−2−3
BUL1−4−200
UBP13−1.5−40−2
YLR352W000−1.5
ECM300000
ELG10+4−2−10
  • NOTE: Relative sensitivity to each drug was determined in comparison with the wild-type cells by semiquantitative spot assay. Fold resistance (+) or fold sensitivity (−) relative to the wild-type parental cells was calculated using the percent survival from duplicate spots at a drug concentration which the wild-type cells retained ∼30% survival. 0 represents strains that have similar sensitivity to that of the wild-type cells to the drugs. The values were derived from average of two to three independent experiments. Concentrations of the drugs are 5-FU, 25 μg/mL; doxorubicin, 20 μg/mL; camptothecin, 20 mmol/L; MNNG, 1 μg/mL.